2025 Q4 -tulosraportti
Vain PDF
58 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 147 | - | - | ||
| 1 000 | - | - | ||
| 450 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·3 min sittenLabiotech.eu 💰 Biotechnology's biggest investments this week! 🚀 🇺🇸 Parabilis Medicines | IPO of 670 million dollars | helical peptides | lead asset for desmoid tumors 🇺🇸 Mineralys Therapeutics, Inc. | Guaranteed offering of 150 million dollars | hypertension treatments | phase 3 in hypertension 🇺🇸 City Therapeutics | Series B of 99.5 million dollars | RNAi treatments | phase 1 in thromboembolic diseases 🇪🇸 ONA Therapeutics | Series B of 86.6 million dollars | antibody-drug conjugates | lead asset for breast cancer 🇳🇴 Circio Holding ASA | Exercise of subscription rights and directed issue of 31.5 million dollars | circular RNA | preclinical program for lead gene therapy 🇦🇺 Racura Oncology | directed issue of 31.2 million dollars | small molecules | phase 3 in acute myeloid leukemia- ·20 min sittenHave read on Facebook that Spain and usa have started buying shares still wow much more expensive later💪😀5 min sitten5 min sittenLabiotech.eu 💰 Biotech's Top Investments This Week! 🚀 🇺🇸 Parabilis Medicines | $670 million IPO | helical peptides | lead asset for desmoid tumors 🇺🇸 Mineralys Therapeutics, Inc. | $150 million underwritten offering | hypertension therapies | phase 3 in hypertension 🇺🇸 City Therapeutics | $99.5 million series B | RNAi therapies | phase 1 in thromboembolic diseases 🇪🇸 ONA Therapeutics | $86.6 million series B | antibody-drug conjugates | lead asset for breast cancer 🇳🇴 Circio Holding ASA | $31.5 million exercise of warrants and private placement | circular RNA | preclinical lead gene therapy program 🇦🇺 Racura Oncology | $31.2 million private placement | small molecules | phase 3 in acute myeloid leukemia
·54 min sittenGood volume today. It will be exciting to see if the guarantors have now managed to sell off the shares that are to be released. I imagine that some of them have borrowed shares and already sold, and that many of their (approximately) 10 million shares have already moved into more long-term hands. A bit too much roller coaster in connection with this emission, but finally we are starting to move into a period without negative price pressure. Circio's bank account is filled to the brim, no emissions or sudden financial antics seem to occur in the foreseeable future, and a completely wild amount of data releases lie ahead of us in the next six months. Now I have held onto my shares for well over a year, and I actually feel more confident than ever that Circio is well-equipped for continued success. Exciting times!
·35 min sittenTaking the weekend with a good conscience now. 🍺
·56 min sitten🧬SAN DIEGO, HERE WE COME🧬 While many are fixated on the stock price day by day, it's worth remembering what's happening June 22-25! Circio will participate in BIO International Convention 2026 – one of the world's most important meeting places for biotech, pharma, investors, and potential partners. ASGCT in Boston gave the company great visibility for the circVec platform. Now they continue directly to BIO for new meetings and opportunities. Patents. Collaboration. Funding secured. International exposure. This is what builds value over time. Exciting weeks ahead. 🚀🧬 I have bought more shares and am holding on 🚂 (Not financial advice. Do your own assessment.)
·1 t sittenStrong finish into the weekend. 💪 Green day, nice comeback after the dip, and we're building ourselves up again — calmly and steadily. Exciting weeks await: BIO in San Diego just around the corner, full cash and runway until 2030. No stress. We are exactly where we should be. Good weekend, folks. Cheers. 🥂 We know what we own. ♟️🧱🍷
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
58 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 min sittenLabiotech.eu 💰 Biotechnology's biggest investments this week! 🚀 🇺🇸 Parabilis Medicines | IPO of 670 million dollars | helical peptides | lead asset for desmoid tumors 🇺🇸 Mineralys Therapeutics, Inc. | Guaranteed offering of 150 million dollars | hypertension treatments | phase 3 in hypertension 🇺🇸 City Therapeutics | Series B of 99.5 million dollars | RNAi treatments | phase 1 in thromboembolic diseases 🇪🇸 ONA Therapeutics | Series B of 86.6 million dollars | antibody-drug conjugates | lead asset for breast cancer 🇳🇴 Circio Holding ASA | Exercise of subscription rights and directed issue of 31.5 million dollars | circular RNA | preclinical program for lead gene therapy 🇦🇺 Racura Oncology | directed issue of 31.2 million dollars | small molecules | phase 3 in acute myeloid leukemia
- ·20 min sittenHave read on Facebook that Spain and usa have started buying shares still wow much more expensive later💪😀5 min sitten5 min sittenLabiotech.eu 💰 Biotech's Top Investments This Week! 🚀 🇺🇸 Parabilis Medicines | $670 million IPO | helical peptides | lead asset for desmoid tumors 🇺🇸 Mineralys Therapeutics, Inc. | $150 million underwritten offering | hypertension therapies | phase 3 in hypertension 🇺🇸 City Therapeutics | $99.5 million series B | RNAi therapies | phase 1 in thromboembolic diseases 🇪🇸 ONA Therapeutics | $86.6 million series B | antibody-drug conjugates | lead asset for breast cancer 🇳🇴 Circio Holding ASA | $31.5 million exercise of warrants and private placement | circular RNA | preclinical lead gene therapy program 🇦🇺 Racura Oncology | $31.2 million private placement | small molecules | phase 3 in acute myeloid leukemia
- ·54 min sittenGood volume today. It will be exciting to see if the guarantors have now managed to sell off the shares that are to be released. I imagine that some of them have borrowed shares and already sold, and that many of their (approximately) 10 million shares have already moved into more long-term hands. A bit too much roller coaster in connection with this emission, but finally we are starting to move into a period without negative price pressure. Circio's bank account is filled to the brim, no emissions or sudden financial antics seem to occur in the foreseeable future, and a completely wild amount of data releases lie ahead of us in the next six months. Now I have held onto my shares for well over a year, and I actually feel more confident than ever that Circio is well-equipped for continued success. Exciting times!·35 min sittenTaking the weekend with a good conscience now. 🍺
- ·56 min sitten🧬SAN DIEGO, HERE WE COME🧬 While many are fixated on the stock price day by day, it's worth remembering what's happening June 22-25! Circio will participate in BIO International Convention 2026 – one of the world's most important meeting places for biotech, pharma, investors, and potential partners. ASGCT in Boston gave the company great visibility for the circVec platform. Now they continue directly to BIO for new meetings and opportunities. Patents. Collaboration. Funding secured. International exposure. This is what builds value over time. Exciting weeks ahead. 🚀🧬 I have bought more shares and am holding on 🚂 (Not financial advice. Do your own assessment.)
- ·1 t sittenStrong finish into the weekend. 💪 Green day, nice comeback after the dip, and we're building ourselves up again — calmly and steadily. Exciting weeks await: BIO in San Diego just around the corner, full cash and runway until 2030. No stress. We are exactly where we should be. Good weekend, folks. Cheers. 🥂 We know what we own. ♟️🧱🍷
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 147 | - | - | ||
| 1 000 | - | - | ||
| 450 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
58 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 min sittenLabiotech.eu 💰 Biotechnology's biggest investments this week! 🚀 🇺🇸 Parabilis Medicines | IPO of 670 million dollars | helical peptides | lead asset for desmoid tumors 🇺🇸 Mineralys Therapeutics, Inc. | Guaranteed offering of 150 million dollars | hypertension treatments | phase 3 in hypertension 🇺🇸 City Therapeutics | Series B of 99.5 million dollars | RNAi treatments | phase 1 in thromboembolic diseases 🇪🇸 ONA Therapeutics | Series B of 86.6 million dollars | antibody-drug conjugates | lead asset for breast cancer 🇳🇴 Circio Holding ASA | Exercise of subscription rights and directed issue of 31.5 million dollars | circular RNA | preclinical program for lead gene therapy 🇦🇺 Racura Oncology | directed issue of 31.2 million dollars | small molecules | phase 3 in acute myeloid leukemia
- ·20 min sittenHave read on Facebook that Spain and usa have started buying shares still wow much more expensive later💪😀5 min sitten5 min sittenLabiotech.eu 💰 Biotech's Top Investments This Week! 🚀 🇺🇸 Parabilis Medicines | $670 million IPO | helical peptides | lead asset for desmoid tumors 🇺🇸 Mineralys Therapeutics, Inc. | $150 million underwritten offering | hypertension therapies | phase 3 in hypertension 🇺🇸 City Therapeutics | $99.5 million series B | RNAi therapies | phase 1 in thromboembolic diseases 🇪🇸 ONA Therapeutics | $86.6 million series B | antibody-drug conjugates | lead asset for breast cancer 🇳🇴 Circio Holding ASA | $31.5 million exercise of warrants and private placement | circular RNA | preclinical lead gene therapy program 🇦🇺 Racura Oncology | $31.2 million private placement | small molecules | phase 3 in acute myeloid leukemia
- ·54 min sittenGood volume today. It will be exciting to see if the guarantors have now managed to sell off the shares that are to be released. I imagine that some of them have borrowed shares and already sold, and that many of their (approximately) 10 million shares have already moved into more long-term hands. A bit too much roller coaster in connection with this emission, but finally we are starting to move into a period without negative price pressure. Circio's bank account is filled to the brim, no emissions or sudden financial antics seem to occur in the foreseeable future, and a completely wild amount of data releases lie ahead of us in the next six months. Now I have held onto my shares for well over a year, and I actually feel more confident than ever that Circio is well-equipped for continued success. Exciting times!·35 min sittenTaking the weekend with a good conscience now. 🍺
- ·56 min sitten🧬SAN DIEGO, HERE WE COME🧬 While many are fixated on the stock price day by day, it's worth remembering what's happening June 22-25! Circio will participate in BIO International Convention 2026 – one of the world's most important meeting places for biotech, pharma, investors, and potential partners. ASGCT in Boston gave the company great visibility for the circVec platform. Now they continue directly to BIO for new meetings and opportunities. Patents. Collaboration. Funding secured. International exposure. This is what builds value over time. Exciting weeks ahead. 🚀🧬 I have bought more shares and am holding on 🚂 (Not financial advice. Do your own assessment.)
- ·1 t sittenStrong finish into the weekend. 💪 Green day, nice comeback after the dip, and we're building ourselves up again — calmly and steadily. Exciting weeks await: BIO in San Diego just around the corner, full cash and runway until 2030. No stress. We are exactly where we should be. Good weekend, folks. Cheers. 🥂 We know what we own. ♟️🧱🍷
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 147 | - | - | ||
| 1 000 | - | - | ||
| 450 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt